Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edvard Smith

Showing results (11-20 of 178) with videos related to

Pageof 18
Sort By:
Clinical Immunology Communications|April 15, 2024
COVID-19 in a patient with Good's syndrome and in 13 patients with common variable immunodeficiencyHannes Lindahl, C I Edvard Smith, Peter Bergman
Lakartidningen|January 29, 2025
[Gene editing is changing the treatment of hereditary diseases]C I Edvard Smith, Rula Zain, Pontus Blomberg
Human Gene Therapy|July 11, 2015
Oligonucleotide Therapies: The Past and the PresentKarin E Lundin, Olof Gissberg, C I Edvard Smith
International Journal of Molecular Sciences|November 27, 2024
Estimating the Number of Polygenic Diseases Among Six Mutually Exclusive Entities of Non-Tumors and CancerC I Edvard Smith, Jan A Burger, Rula Zain
Iscience|July 20, 2022
Estimating the number of diseases - the concept of rare, ultra-rare, and hyper-rareC I Edvard Smith, Peter Bergman, Daniel W Hagey
FEBS Letters|September 11, 2002
Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA)Juhana E Heinonen, C I Edvard Smith, Beston F Nore
Frontiers in Cell and Developmental Biology|March 29, 2021
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse EffectsH Yesid Estupiñán, Anna Berglöf, Rula Zain, et al.
Current Molecular Medicine|September 28, 2007
Gene expression signatures in primary immunodeficiencies: the experience from human disease and mouse modelsK Emelie M Blomberg, C I Edvard Smith, Jessica M Lindvall
FEBS Letters|July 19, 2005
Functional replacement of Drosophila Btk29A with human Btk in male genital development and survivalNoriko Hamada, Carl-Magnus Bäckesjö, C I Edvard Smith, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 15, 2019
Chemical Development of Therapeutic OligonucleotidesKarin E Lundin, Olof Gissberg, C I Edvard Smith, et al.
Pageof 18

Showing results (11-20 of 178) with videos related to

Sort By:
Pageof 18
Clinical Immunology Communications|April 15, 2024
COVID-19 in a patient with Good's syndrome and in 13 patients with common variable immunodeficiencyHannes Lindahl, C I Edvard Smith, Peter Bergman
Lakartidningen|January 29, 2025
[Gene editing is changing the treatment of hereditary diseases]C I Edvard Smith, Rula Zain, Pontus Blomberg
Human Gene Therapy|July 11, 2015
Oligonucleotide Therapies: The Past and the PresentKarin E Lundin, Olof Gissberg, C I Edvard Smith
International Journal of Molecular Sciences|November 27, 2024
Estimating the Number of Polygenic Diseases Among Six Mutually Exclusive Entities of Non-Tumors and CancerC I Edvard Smith, Jan A Burger, Rula Zain
Iscience|July 20, 2022
Estimating the number of diseases - the concept of rare, ultra-rare, and hyper-rareC I Edvard Smith, Peter Bergman, Daniel W Hagey
FEBS Letters|September 11, 2002
Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA)Juhana E Heinonen, C I Edvard Smith, Beston F Nore
Frontiers in Cell and Developmental Biology|March 29, 2021
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse EffectsH Yesid Estupiñán, Anna Berglöf, Rula Zain, et al.
Current Molecular Medicine|September 28, 2007
Gene expression signatures in primary immunodeficiencies: the experience from human disease and mouse modelsK Emelie M Blomberg, C I Edvard Smith, Jessica M Lindvall
FEBS Letters|July 19, 2005
Functional replacement of Drosophila Btk29A with human Btk in male genital development and survivalNoriko Hamada, Carl-Magnus Bäckesjö, C I Edvard Smith, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 15, 2019
Chemical Development of Therapeutic OligonucleotidesKarin E Lundin, Olof Gissberg, C I Edvard Smith, et al.
Pageof 18